Gauglitz GG - Search Results

1

Efficacy of cream-based novel formulations of hyaluronic acid of different molecular weights in anti-wrinkle treatment.

Pavicic T, Gauglitz GG, Lersch P, Schwach-Abdellaoui K, Malle B, Korting HC, Farwick M. Pavicic T, et al. Among authors: gauglitz gg. J Drugs Dermatol. 2011 Sep;10(9):990-1000. J Drugs Dermatol. 2011. PMID: 22052267 Clinical Trial.

2

Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients.

Pavicic T, Ruzicka T, Korting HC, Gauglitz G. Pavicic T, et al. J Drugs Dermatol. 2010 Jun;9(6):690-5. J Drugs Dermatol. 2010. PMID: 20645533

3

Fifty-kDa hyaluronic acid upregulates some epidermal genes without changing TNF-α expression in reconstituted epidermis.

Farwick M, Gauglitz G, Pavicic T, Köhler T, Wegmann M, Schwach-Abdellaoui K, Malle B, Tarabin V, Schmitz G, Korting HC. Farwick M, et al. Skin Pharmacol Physiol. 2011;24(4):210-7. doi: 10.1159/000324296. Epub 2011 Mar 11. Skin Pharmacol Physiol. 2011. PMID: 21412035 Free article.

4

[Modern soft tissue augmentation--away from treating the single fold to volume replacement in the whole face].

Pavicic T, Gauglitz GG. Pavicic T, et al. Among authors: gauglitz gg. MMW Fortschr Med. 2012 Sep 10;154(15):51-2, 54. doi: 10.1007/s15006-012-1082-3. MMW Fortschr Med. 2012. PMID: 22997941 German. No abstract available.

5

Calcium Hydroxyapatite Filler With Integral Lidocaine CaHA (+) for Soft Tissue Augmentation: Results from an Open-Label Multicenter Clinical Study.

Pavicic T, Sattler G, Fischer T, Dirschka T, Kerscher M, Gauglitz G, Dersch H, Kravtsov M, Heide I, Prager W. Pavicic T, et al. J Drugs Dermatol. 2022 May 1;21(5):481-487. doi: 10.36849/JDD.6737. J Drugs Dermatol. 2022. PMID: 35533030

6

[Emerging strategies for the prevention and therapy of excessive scars].

Gauglitz GG, Pavicic T. Gauglitz GG, et al. MMW Fortschr Med. 2012 Sep 10;154(15):55-8. doi: 10.1007/s15006-012-1083-2. MMW Fortschr Med. 2012. PMID: 22997942 German. No abstract available.

7

[Management of hypertrophic scars and keloids].

Gauglitz GG, Pavicic T, Ruzicka T. Gauglitz GG, et al. MMW Fortschr Med. 2010 Oct 21;152(42):40-3; quiz 44. MMW Fortschr Med. 2010. PMID: 21140952 Review. German. No abstract available.

8

Botulinum toxin A for the treatment of keloids.

Gauglitz GG, Bureik D, Dombrowski Y, Pavicic T, Ruzicka T, Schauber J. Gauglitz GG, et al. Skin Pharmacol Physiol. 2012;25(6):313-8. doi: 10.1159/000342125. Epub 2012 Aug 31. Skin Pharmacol Physiol. 2012. PMID: 22948093 Free article.

9

Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study.

Fischer T, Sattler G, Prager W, Rzany B, Pavicic T, Gauglitz G, Weissenberger P, Riaz S. Fischer T, et al. J Drugs Dermatol. 2020 May 1;19(5):461-469. J Drugs Dermatol. 2020. PMID: 32484631 Clinical Trial.

10

Safety of Cohesive Polydensified Matrix Cross-Linked Hyaluronic Acid Volumizing Gel in Temporal Hollows and Cheeks: A Prospective, Open-Label, Postmarket Study.

Pavicic T, Sattler G, Prager W, Fischer T, Gauglitz G, Hofmann M, Dersch H, Riaz S, Kerscher M. Pavicic T, et al. Dermatol Surg. 2021 Oct 1;47(10):1359-1364. doi: 10.1097/DSS.0000000000003176. Dermatol Surg. 2021. PMID: 34417392 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

104 results

Search Page